Connect with us

Business Insider

Joel Seth Aronson Recognized for Excellence in Pharmacy

Avatar

Published

on

NATICK, Mass., April 28, 2021 /PRNewswire/ — Joel Seth Aronson is a distinguished biographee of Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are chosen from among a pool of the most prominent professionals and are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Joel Seth Aronson Recognized for Excellence in Pharmacy

Drawn to a career in pharmacy due to his longstanding desire to help people, Mr. Aronson was further inspired by his grandfather, who was a pharmacist, as well as his early experience working in an Eckerd drugstore warehouse. He initially earned a Bachelor of Science degree in pharmacy from the College of Pharmacy at the University of Louisiana at Monroe in 1972. Soon thereafter, he refined his skills as a retail pharmacy intern with Steven’s Pharmacy and Brookline Pharmacy before obtaining his licensure as a pharmacist in the states of Louisiana, Massachusetts, and Florida. Mr. Aronson has subsequently excelled as an inpatient clinical pharmacy specialist and conducted considerable work verifying physicians’ orders in addition to discharging and counseling veterans.

Mr. Aronson began his career as a pharmacist with Boston City Hospital in 1974, a position he held for over 20 years until  the hospital merged with the Boston University Medical Center Hospital to become Boston Medical Center in 1996. He flourished in the same post with the Boston Medical Center until 2002. In 2003, he worked as a part-time pharmacist with the Family Med Pharmacy, the Costco Pharmacy, CVS Procare, and the Target Pharmacy, prior to serving the Providence Veterans Affairs Medical Center in Rhode Island as a full-time pharmacist in 2004. Mr. Aronson was promoted to a clinical pharmacy specialist position at the VA Medical Center in 2011, a role in which he remained until his retirement in 2019.

Attributing much of his success to being compassionate and a good listener, Mr. Aronson has contributed his time and resources to a number of other professional endeavors over the course of his career. During his tenure with the Boston Medical Center, he was active as a member of the patient/family education steering committee and at the Providence VA hospital he worked and served as a volunteer trainer for pharmacy technicians, pharmacy students, and pharmacy residents throughout his career. In order to stay aware of developments in his field, Mr. Aronson maintained his professional affiliations with the American Pharmacists Association, the American Society of Health-System Pharmacists, the Massachusetts Pharmacists Association, and the Massachusetts Society of Health-System Pharmacists.

As a testament to his achievements throughout his career, Mr. Aronson has been presented with a number of honors and accolades, including the I Care Leadership Award pin from the United States Department for Veterans Affairs. However, he cites his greatest accomplishments as his ability to do the right thing and train people so they can help others. Some additional highlights of Mr. Aronson’s career include helping to manage the weekend and evening schedules for his fellow pharmacists, the commendation he received for working during a blizzard in 1978, being elected as a union shop steward to represent the pharmacy department at both Boston City Hospital and Boston Medical Center, and preventing an attempted armed robbery of narcotics from the pharmacy at the Boston City Hospital.         

About Marquis Who’s Who®:

Since 1899, when A. N. Marquis printed the First Edition of Who’s Who in America®, Marquis Who’s Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who’s Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who’s Who® website at www.marquiswhoswho.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/joel-seth-aronson-recognized-for-excellence-in-pharmacy-301279581.html

SOURCE Marquis Who’s Who

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://markets.businessinsider.com/news/stocks/joel-seth-aronson-recognized-for-excellence-in-pharmacy-1030360347

Business Insider

Legendary investor Jeremy Grantham told us why he went all in on climate-crisis investing after retiring from portfolio management – and shared the one career path he’d choose if he could do it all…

Avatar

Published

on

jeremy grantham
Jeremy Grantham, Co-founder and Chief Investment Strategist of GMO, takes notes during an Oxford-style debate on financial innovation hosted by “The Economist” magazine at Pace University in New York October 16, 2009.

  • Jeremy Grantham went all in on climate investing after retiring from managing money 15 years ago.
  • He explains why climate change investing both benefits the environment and promises high returns.
  • He also shares the one investing career path he’d choose now if he could start all over again.
  • See more stories on Insider’s business page.

Before President Biden’s infrastructure proposal gave an inkling of how green tech could massively reshape the future of energy, Jeremy Grantham had already been working on climate-change investing for over a decade.

The co-founder of Boston-based fund manager GMO redefined his job description to work on big issues including the climate crisis, resource shortages, and growth rates after retiring from portfolio management 15 years ago.

“So I started preaching the significance of climate change as the most important input into our portfolio going forward,” he said in an interview. “And I can assure you that there was a lot of eye-rolling.”

It made sense why his early listeners were bored. While oil and gas companies constitute just 2.3% of the S&P 500 index today, they made up more than 15% of the premier US large-cap index in 2008.

But the market has adjusted vastly over the past 10 years. A symbolic yet pivotal sign of the ongoing transition to greener renewable energy is the removal of oil giant Exxon Mobil from the blue-chip Dow Jones Industrial Average index in September last year.

For Grantham, who has pledged 98% of his billionaire-dollar wealth to his environmental foundation, it was clear from the get-go that businesses working on solutions to the climate crisis are going to be “the biggest thing coming down the pike.”

With the rising popularity of environmental, social, and governance investing and a clean energy revolution driven by the President’s infrastructure plan, the moment has arrived for many of these businesses and technologies. There are even talks of a “green bubble” as investors have piled into renewable energy stocks and driven up sky-high valuations.

“There are certainly some bubbly elements in the green part of the industry,” Grantham said. “We believe at GMO that the energy efficiency and the greening are so complicated and diffused that you can dig through it and find cheaper components.”

Indeed, the firm in 2015 launched the now $417.6 million GMO Climate Change fund, which is managed by Lucas White and Thomas Hancock. The fund has significantly invested in the electric vehicle value chain, biofuels, solar and wind energy, as well as clean energy materials.

The race of our lives

As investors wake up to the compelling economics of climate-friendly investing, global governments have also increasingly put talent and resources behind green technologies.

“Everyone is in a way beginning to compete,” Grantham said. “They are not only beginning to compete to be green, but they are beginning to compete for the green industries.”

From the US to China, major economies are fighting to be the leaders in everything from solar panels and wind storage to electric vehicles and battery materials. China, in particular, has taken the lead in many “industries of the future,” dominating 80% of the global solar panel market, for example.

“They are moving, up till now, much much faster to make sure that they are central players in the greening of the global economy,” he said. “And it would be really foolish if Europe and the US did not make a big effort to compete.”

The race has already accelerated as global governments speed up their commitments to cutting greenhouse gas emissions. Since the Texas power outage in February raised issues of the three separate electrical grid systems in the US, there have also been more talks of investing in energy efficiency and grid improvement.

Grantham believes that the transition to green technology could also benefit and sustain the global economy in the long run.

“It may come with some extra inflationary pressure but I don’t mind that,” he said. “I think it’s the price worth paying to have more people drawn into manufacturing, into the labor market, to have more pressure on wages from these terrible levels they sank down through, and to end up with a more efficient economy.”

‘Do something that turns you on’

As a legendary investor who successfully called three market bubbles, Grantham is nevertheless not recommending ambitious young people to follow in his footsteps.

In fact, he thinks American capitalism is in a bad place. “It’s monopolistic, it’s too powerful, and it’s not really free competition,” he said. “It doesn’t have enough new enterprises, and the number of companies that are only one or two years old is half the percentage it used to be in the mid-1970s.”

In his view, venture capital is the one last great exceptionalism in America. “If I was starting again, I would do venture capital,” he said.

Grantham said starting a new firm and being associated with the US venture capital industry is “thoroughly exciting,” because it is not only dominant by size and success but has also attracted the “brightest and best people.”

He also recommends young people to get involved in the greening of the economy either in the non-profit world, the political world, or the venture capital world.

“I think the green VC will move the dial for our well-being as much as anything, as much as $1 of grant-making to anybody. And secondly, I think they’re a candidate for the highest future return,” he said. “How often do you get to do what you think is exactly the right thing to do and to make money.”

More than anything, the 82-year-old investor said it is paramount to “do something that turns you on.”

“I can assure you, you will get old much quicker than you think. Do not hang about, do not waste time,” he said. “Do what you love and do it vigorously.”

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://markets.businessinsider.com/news/stocks/jeremy-grantham-interview-explains-climate-change-investing-opportunities-career-advice-2021-5-1030440785

Continue Reading

Business Insider

Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis

Avatar

Published

on

  • Interim data from the first 60 patients with NASH on track to be reported in the fourth quarter of 2021
  • Enrollment continuing for up to 180 patients, with full topline results expected to be reported in the first half of 2022

SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) — Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it has enrolled the first 60 patients in its MET642 Phase 2a trial. The Company remains on track to report interim results in the fourth quarter of 2021 after these patients have completed 16 weeks of treatment.     

“The promise of an optimized FXR agonist has motivated investigators, and most importantly patients, to participate in our study,” said Hubert C. Chen, M.D., chief medical officer, Metacrine. “We are grateful for their enthusiasm and support in reaching this important milestone, as well as for the hard work of our clinical operations team in a challenging Covid-19 environment.”     

The Phase 2a study (NCT04773964) is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity (as measured by liver fat reduction) of MET642 (3 mg and 6 mg). Full topline trial results of up to 180 patients are expected to be reported in the first half of 2022.

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases.   Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials.   The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH.   MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes.   MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH.   To learn more, visit www.metacrine.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements about the design, progress, timing, scope and results of clinical trials; the anticipated timing of disclosure of results of clinical trials; statements regarding the therapeutic potential of MET409 and MET642; the differentiated nature of Metacrine’s FXR program; . Words such as “may,” “will,” “expect,” “plan,” “aim,” “projected,” “likely, ”anticipate,” “estimate,” “intend,” “potential,” “prepare,” “perceived,” “believes” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Metacrine’s expectations and assumptions that may never materialize or prove to be incorrect. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks and uncertainties regarding regulatory approvals for MET409 or MET642; potential delays in initiating, enrolling or completing any clinical trials; potential adverse side effects or other safety risks associated with Metacrine’s product candidates; competition from third parties that are developing products for similar uses; and Metacrine’s ability to obtain, maintain and protect its intellectual property. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Metacrine’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2021, and in Metacrine’s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as required by law, Metacrine assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. 


Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://markets.businessinsider.com/news/stocks/metacrine-achieves-enrollment-target-for-met642-phase-2a-trial-interim-analysis-1030440749

Continue Reading

Business Insider

StrikeForce Technologies Provides Shareholders a Business Update

Avatar

Published

on

EDISON, N.J., May 18, 2021 (GLOBE NEWSWIRE) — StrikeForce Technologies, Inc. (OTCQB: SFOR), a cyber security company that provides next-gen cyber, privacy & data protection solutions for business and home users issues an update to its shareholders on its current business activities and future growth potential.

“So many great things have transpired for us since our last shareholder update on November 10, 2020,” says Mark L. Kay, CEO of StrikeForce, “just look at some of our key milestones (below) that clearly define a company that has the vision, the determination and the tenacity to get the job done.”

  • 11/24/20 – StrikeForce receives SEC Qualification for its Regulation A Tier II offering to raise $2,500,000
  • 2/18/21 – StrikeForce announces that PrivacyLok™ is commercially available
  • 3/8/21 – StrikeForce announces that SafeVchat™ is commercially available
  • 3/16/21 – StrikeForce finishes paying off all convertible debt
  • 4/16/21 – StrikeForce acquires Cybersecurity Risk Solutions LLC.
  • 5/11/21 – Strikeforce receives SEC Qualification Regulation A Tier ll offering raise of $7,500,000
  • 5/13/21 – StrikeForce’s shares were up listed to trade on the OTCQB
  • 5/17/21 – StrikeForce hires Brian Hart, a seasoned cyber security sales executive

“While meeting the above milestones, they are all extremely important for our growth trajectory, the really exciting part starts now,” says Kay, “that’s the sales, marketing & revenue phase.”

“To start with, we have chosen one of the industry’s leading digital marketing companies to redesign our website and create a proven and aggressive multi-channel marketing campaign similar to many of their other fortune customers. In addition to the traditional digital marketing campaigns, SafeVchat commercials will also be seen on Times Square billboards, Facebook, LinkedIn, Targeted Display Ads and heard on local and national radio shows,” says Kay.

Additionally, and as previously reported on 5/11/21, CRS has secured a partnership with James A. Connors Associates, Inc. (JACA), a leading independent insurance and risk management broker. The partnership enables JACA and CRS to grow and strengthen their cyber offerings in the insurance marketplace, like JACA’s new cyber program to thousands of personal and commercial clients.

“Now you can see why I am so excited about everything that’s going on,” says Kay, “for the longest time we just didn’t have the marketing capital or resources to grow the company like we wanted to. But times have changed, we started cleaning up our balance sheet, we paid-off our convertible notes, we introduced two new products (SafeVchat & PrivacyLok), we bought a company that offers pre-breach & post-breach services, we are hiring one of the nation’s leading digital marketing companies to market our products and most of all we have the financial means to afford it. That’s something we never had before, that’s why I anticipate strong revenues & growth later on this year,” says Kay.

About StrikeForce TechnologiesInc.
StrikeForce Technologies helps to prevent cyber theft and data security breaches for consumers, corporations, and government agencies. It provides powerful two-factor, “Out-of-Band” authentication, keystroke encryption along with mobile solutions. StrikeForce Technologies, Inc. (OTCQB:SFOR) is headquartered in Edison, N.J., and can be reached at www.strikeforcetech.com or by phone at (732) 661-9641 or toll-free at (866) 787-4542.

Safe Harbor Statement:
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the sales of the company’s identity protection software products into various channels and market sectors, the issuance of the Company’s pending patent applications, COVID-19, and the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the company.

Media contact:
Kevin Blomberg
Fusion Public Relations
kevin.blomberg@fusionpr.com
(617) 869-1413


Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://markets.businessinsider.com/news/stocks/strikeforce-technologies-provides-shareholders-a-business-update-1030440758

Continue Reading

Business Insider

Cramer Weighs In On Beyond Meat, Snowflake, More

Avatar

Published

on

Jim Cramer said on CNBC’s “Mad Money Lightning Round” he would buy more shares of Anthem Inc (NYSE:ANTM). He also likes UnitedHealth Group Inc (NYSE:UNH) and Humana Inc (NYSE:HUM).

Beyond Meat Inc (NASDAQ:BYND) is going to be a winner in the long term, said Cramer. He said it is a loser in the short term.

Cramer would hold Snowflake Inc (NYSE:SNOW) because he has faith in CEO Frank Slootman.

Three EV battery stocks didn’t report good earnings on Monday, so investors in Tuscan Holdings Ord Shs (NASDAQ:THCB) are going to have to take some pain, said Cramer.

AFLAC Incorporated (NYSE:AFL) is a good insurance company, not great and not bad, said Cramer.

United Microelectronics Corp (NYSE:UMC) is a buy at this level, said Cramer. It is doing well and he is okay with it.

Emergent Biosolutions Inc (NYSE:EBS) is a disaster, said Cramer.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://markets.businessinsider.com/news/stocks/cramer-weighs-in-on-beyond-meat-snowflake-more-1030440739

Continue Reading
AR/VR3 days ago

Next Dimension Podcast – Pico Neo 3, PSVR 2, HTC Vive Pro 2 & Vive Focus 3!

Blockchain5 days ago

IRS & DOJ Set Sights on Binance to Root Out Illicit Activity

Blockchain5 days ago

Hong Kong in Talks with China to Stretch Cross-Border Testing of Digital Yuan

Big Data5 days ago

Disney’s streaming growth slows as pandemic lift fades, shares fall

Cyber Security3 days ago

Online Cybersecurity Certification Programs

Esports3 days ago

Technoblade’s Minecraft settings

Blockchain3 days ago

Proof-of-Work Cryptocurrencies Spikes After Elon Musk Ditches Bitcoin

Blockchain5 days ago

Elon Musk’s Tesla Looking to Accept Energy-Efficient Cryptocurrencies

Blockchain News5 days ago

MicroStrategy Acquires an Additional 271 Bitcoins for $15 Million

Esports5 days ago

Playbase offers an instant solution to organizing simple and cost-effective competitive gaming platforms

Big Data5 days ago

Elon Musk on crypto: to the mooooonnn! And back again

Energy5 days ago

AlphaESS lance de nouveaux produits et programmes au salon Smart Energy Conference & Exhibition de 2021

ZDNET5 days ago

US pipeline ransomware attack serves as fair warning to persistent corporate inertia over security

North America
Esports3 days ago

Extra Salt, O PLANO secure wins in cs_summit 8 closed qualifier openers

Aviation5 days ago

The World’s Most Interesting Boeing 747 Uses

Esports5 days ago

Valorant Error Code VAN 81: How to Fix

Esports5 days ago

CS:GO Update 1.37.9.1 adds several updates to new map Ancient

AI4 days ago

Shiba Inu (SHIB) Mania, Dogecoin, Tesla’s Bitcoin Halt and Crypto Market Volatility: The Weekly Recap

Energy5 days ago

How Young Entrepreneur Jeff Clayton Is Innovating the Dropshipping Logistics Industry

Energy5 days ago

Aero-Engine Coating Market to grow by USD 28.43 million|Key Drivers, Trends, and Market Forecasts|17000+ Technavio Research Reports

Trending